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ABSTRACT
Background    Oral squamous cell carcinoma is a prev-
alent and frequently lethal malignancy worldwide. Exis-
tence of treatment-resistant cancer stem cells is consid-
ered to be associated with tumor formation, recurrence 
and metastasis. Wnt/beta-catenin signal is one of the 
crucial signaling pathways for cancer stem cells. Wnt/
beta-catenin signal inhibitor may reduce the population 
of cancer stem cells and improve therapeutic effects on 
the cancers.
Methods    The effects of three derivatives of Wnt/
beta-catenin signal inhibitors, HC-1, IC-2 and PN3-13, 
which we recently developed, on oral squamous cell car-
cinoma cell line HSC2, were examined by luciferase re-
porter assay, WST assay, cell sorting assay and apoptosis 
assay.
Results    The reporter assay showed that these small 
molecule compounds reduced Wnt/beta-catenin tran-
scriptional activity in HSC2 cells. Of these compounds, 
IC-2 and PN3-13 inhibited cell viability in a dose-de-
pendent manner, whereas HC-1 did not at even higher 
concentrations. Notably, however, the cell-sorting assay 
revealed that HC-1 significantly reduces the CD44-pos-
itive population of oral squamous cell carcinoma cells, 
compared to other compounds without affecting cell 
viability. In addition, HC-1 increases the cytotoxicity of 
HSC2 cells to 5-fluorouracil. The combination treatment 
of HC-1 with 5-fluorouracil significantly increased the 
apoptotic cells whereas treatment by either compound 
did not. 
Conclusion    These data suggest that HC-1 is an ef-
fective compound to target cancer stem cells, and the 
combination treatment of HC-1 and 5-fluorouracil can 
stimulate the tumor suppressive effect on oral squamous 
cell carcinoma cells. 
Key words    5-fluorouracil; cancer stem cells; oral 
squamous cell carcinoma; small molecule compound; 
Wnt/beta-catenin signal inhibitor
Oral squamous cell carcinoma (OSCC) is a major prev-
alent malignancy throughout the world, and its mortal-
ity rate is approximately 50%.1–3 Despite advances in 
conventional treatments including surgery, radiotherapy 
and chemotherapy, the survival rate for OSCC has not 
improved significantly over the past few decades.4 High 
mortality seems to be induced by the emergence of ther-
apy-resistant local recurrences and the development of 
distant metastases.5, 6 Thus, more effective therapeutic 
strategy is urgently required for improving the clinical 
outcome of OSCC.
 Recent data have demonstrated that multiple can-
cers, including OSCC, contain a small subpopulation of 
cells that have stem cell-like properties, so-called cancer 
stem cells (CSCs).7–9 CSCs have the unique features of 
self-renewal and asymmetrical division, and show resis-
tance to radio- and chemotherapy.10, 11 CSCs in OSCC 
were first isolated using cell surface marker CD44.5 The 
existence of CSCs may explain the high rate of recur-
rences after conventional therapies. Therefore, targeting 
of CSCs is considered to provide a new strategy to im-
prove therapeutic effects on many cancers. 
 Wnt/beta-catenin signal is one of the crucial sig-
naling pathways for self-renewal and differentiation of 
CSCs.12, 13 Expression levels of stem cell related genes, 
including CD44, are regulated by this pathway. We 
have previously shown that Wnt/beta-catenin signal is 
suppressed during the hepatic differentiation process of 
human mesenchymal stem cells (MSCs),14, 15 and recent-
ly developed small molecule compounds, derivatives 
of Wnt/beta-catenin signal inhibitors, that efficiently 
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suppress Wnt/beta-catenin transcriptional activity in hu-
man MSCs.16, 17 In the present study, we found that these 
compounds also suppress the Wnt/beta-catenin signal 
in human OSCC cell line HSC2. Of these compounds, 
HC-1 effectively reduced the rate of CD44-positive cells 
without affecting cell viability. In addition, HC-1 sensi-
tized HSC2 cells to 5-fluorouracil (5-FU), a DNA/RNA 
synthesis inhibitor,18 by virtue of enhancement of apop-
totic cell death.
MATERIALS AND METHODS
Compounds
We recently developed new small molecular compounds, 
the derivatives of the compounds which were originally 
reported to be Wnt/beta-catenin signal inhibitors of col-
orectal cancer cells,19–21 for human MSCs.17 These com-
pounds include HC-1, a derivative of hexachlorophene; 
IC-2, a derivative of ICG-001; and PN-3-13, a derivative 
of PNU-74654. The compounds were dissolved in di-
methylsulfoxide (DMSO) whose final concentration was 
1%, and used in the experiments.
Cells and culture
Human OSCC cell line, HSC2 were kindly provided by 
Dr. H. Kugoh (Tottori Univ., Yonago, Japan). The cells 
were incubated in DMEM (Life Technologies, Carlsbad, 
CA) supplemented with 10% FBS, 1% penicillin strepto-
mycin, 2 mM L-glutamine, 0.2% NaHCO3 and 3.5 g/L 
D-glucose with or without chemical compounds.
Luciferase reporter assay 
HSC2 cells were seeded onto a 24-well plate at a densi-
ty of 5 × 104 cells/well. After overnight incubation, the 
cells were transfected with pTCF4-CMVpro-Fluc and 
pRL-CMV-Rluc plasmids14 using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA) for 4 h, and then treated with 
various concentrations of compounds for 48 h. The lu-
ciferase activity was measured by Dual-LuciferaseR Re-
porter assay system (Promega, Madison, WI) and Mini-
Lumat LB 9506 (Berthold Technologies, Bad Wildbad, 
Germany).
WST assay
HSC2 cells were seeded onto a 96-well plate at a density 
of 2.5 × 103 cells/well. After overnight incubation, the 
cells were treated with various concentrations of com-
pounds for 48 h. Cell viability was analyzed by WST 
assay using Cell Counting kit-8 (Dojindo, Kumamoto, 
Japan) and Micro plate reader (Tecan, Männedorf, Swit-
zerland). IC50 values are 50% cell growth inhibitory 
concentrations of each compound, which are obtained 
from the following equation: IC50 = 10^[LOG(A/B)
x(50-C)/(D-C) + LOG(B)] - A, a higher concentration of 
two values that sandwich IC50; B, a lower concentration 
of two values that sandwich IC50; C, cell viability (%) at 
B; D, cell viability (%) at A.
Flow cytometry
HSC2 cells were seeded onto 10 cm plate at a density 
of 5 × 105 cells/well. After overnight incubation, the 
cells were treated with indicated concentrations of com-
pounds for 48 h. Then cells were sorted by a cell sorting 
system (FACS-Aria, Becton Dickinson and Company, 
Franklin Lakes, NJ) using CD44 mouse antibody (Cell 
Signaling Technology, Danvers, MA) and goat-anti-
mouse IgG Alexa 488 (Life Technologies, Carlsbad, 
CA).
Apoptosis assay
HSC2 cells were seeded onto a 6-well plate at a den-
sity of 1 × 105 cells/well. After overnight incubation, 
the cells were treated with 0.1 µM 5-FU and/or 0.1 µM 
HC-1 for 48 h. Then, the cells were stained by annex-
in-V and PI using an annexin-V-FLOUS Staining Kit 
(Roche Diagnostics, Indianapolis, IN), photographed 
with a microscope (IX-71) (Olympus, Tokyo, Japan) and 
analyzed using an image analysis system (inForm 2.0) 
(PerkinElmer, Norwalk, CT).
Western blot analysis
Cell lysis proteins (12.5 µg) were subjected to Western 
blot assay. The rabbit polyclonal antibody against be-
ta-catenin (Cell Signaling Technology, Danvers, MA) 
and goat polyclonal antibody against Actin (Santa Cruz 
Biotechnology, Santa Cruz, CA) were used. Actin was 
served as an internal control.
Statistical analysis
All the values were expressed as mean ± SD. Multiple 
comparison was performed by a one-way ANOVA fol-
lowed by a Tukey HSD test or Games-Howell test using 
predictive analytics software (SPSS, Chicago, IL). The 
differences between the two groups were analyzed by an 
unpaired two-tailed Student’s t-test. A P-value less than 
0.05 was considered to be significant. 
RESULTS
Small molecule compounds inhibit TCF4/beta-cat-
enin transcriptional activity in OSCC HSC2 cells
To examine the effect of derivatives of Wnt/beta-catenin 
signal inhibitors on TCF4/beta-catenin transcriptional 
activity in OSCC cells, a luciferase reporter assay was 
performed using HSC2 cells. The cells were treated 
with various concentrations of HC-1, IC-2, PN3-13 or 
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5-FU for 48 h (Fig. 1). All the derivatives significantly 
suppressed the luciferase activity in a dose-dependent 
manner, indicating that these compounds possess an in-
hibitory effect on Wnt/beta-catenin signal in HSC2 cells 
(Fig. 1)
Cell viability assay of HSC2 cells treated with 
chemical compounds 
To investigate the effect of Wnt/beta-catenin signal 
inhibitors on proliferation of HSC2 cells, cell viability 
was analyzed by WST assay. The cells were treated with 
various concentrations of compounds for 48 h. IC-2, 
PN3-13 and 5-FU significantly reduced cell viability in 
a dose-dependent manner with IC50 at 31 µM, 9.6 µM 
and 4.1 µM, respectively (Fig. 2). HC-1 had little effect 
on cell viability up to 50 µM, whereas it reduced that to 
about 50% at 100 µM. 
HC-1 reduces CD44-positive population in HSC2 
cells
Growing evidence suggests that CSCs are highly resis-
tant to conventional therapies and are responsible for 
recurrence and metastasis.10, 11 Thus, the suppression of 
CSCs seems to be important for cancer therapy. To ex-
amine the effect of Wnt/beta-catenin inhibitors on CSC 
population, we next performed FACS analysis using an-
tibody specific to CD44, a CSC marker for OSCC (Fig. 
3A).5 HSC2 cells were treated with these compounds for 
48 h at two different concentrations (lower and higher) 
whose values are close to the IC50 of the cell viability 
assay (Fig. 2). Both concentrations displayed similar 
effects on the CD44-positive population. IC-2 showed a 
modest decrease of CD44-positive cells, whereas PN3-
13 and 5-FU did not significantly change the rate, com-
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Fig. 1. Small molecule compounds inhibit TCF4/beta-catenin transcriptional activity in OSCC HSC2 cells. TCF4/beta-catenin transcrip-
tional activity was examined by luciferase reporter assay with indicated concentrations of 5-FU (0–100 µM), HC-1 (0–100 µM), IC-2 
(0–100 µM) and PN3-13 (0–50 µM). The cells were transfected with pTCF4-CMVpro-Fluc plasmid and internal control pRL-CMV-
Rluc plasmid, and luciferase activity of pTCF4-CMVpro-Fluc (Fluc) was normalized by the activity of pRL-CMV-Rluc (Rluc).*P < 0.05, 
compared to 0 µM of each compound. The statistics were examined by unpaired Student’s t-test. Data are shown as mean ± SD of three 
experiments. 5-FU, 5-fluorouracil; OSCC, Oral squamous cell carcinoma.
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pared to DMSO treatment (Fig. 3B). Interestingly, HC-1 
clearly and more effectively reduced the CD44-positive 
population, compared to other compounds (Fig. 3B), 
suggesting that HC-1 efficiently targets CSCs of OSCC 
cells. 
Combined treatment using 5-FU and HC-1 in-
creases the rate of apoptotic cell death 
The decrease of the CD44-positive population by HC-1 
treatment raised the possibility that HC-1 increases the 
cytotoxicity of conventional anticancer drugs, such as 
5-FU. To test the effect of the combination treatment, 
HSC2 cells were treated with 0 to 100 µM 5-FU alone 
or in combination with HC-1 (Fig. 4A). The concentra-
tion of HC-1 used was 50 µM, which showed no inhibi-
tory effect on HSC2 proliferation (Fig. 2). Notably, HC-1 
significantly enhanced the cytotoxicity of 5-FU even at 
0.1 µM (Fig. 4A). To investigate how HC-1 enhanced the 
cytotoxicity of 5-FU, we examined whether apoptosis 
of the cells is induced by the treatment of 5-FU with 
or without HC-1 (Fig. 4B). Annexin -V and PI staining 
revealed that apoptosis increased when the cells were 
treated with 5-FU in combination with HC-1, compared 
to DMSO treatment (Figs. 4B and C). No induction of 
apoptosis was observed in the cells treated with HC-1 
or 5-FU alone, which is consistent to the cell viability 
assay (Figs. 2 and 4A). These results suggest that HC-1 
increases the cytotoxic effect of 5-FU through enhance-
ment of apoptosis in HSC2 cells.
DISCUSSION
CSCs have self-renewal ability, higher tumor forming 
capacity, and show resistance to chemotherapy.10, 11 
Thus, CSCs are thought to be a key factor for tumor-
igenesis, progression, metastasis and recurrence after 
treatments. To improve therapeutic effect on cancers, 
targeting the CSCs is considered to provide an effective 
strategy. CSCs use many of the same signaling pathways 
that have been found in normal stem cells, such as Wnt/
beta-catenin, Notch and Hedgehog.22–24 Wnt/beta-cat-
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Fig. 2. Cell viability assay of HSC2 cells treated with small molecule compounds. Cells were treated with increasing concentrations of 
5-FU, HC-1, IC-2 and PN3-13 for 48 h. Cell viability was analyzed by WST assay. *P < 0.05, compared to 0 µM of each compound. The 
statistics were examined by unpaired Student’s t-test. Data are shown as mean ± SD of three experiments. 5-FU, 5-fluorouracil.
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Fig. 3. HC-1 reduces CD44-positive population in HSC2 cells. Cells were treated by 5-FU, HC-1, IC-2 and PN3-13 for 48 h with indicated 
concentrations and sorted by cell sorting system using CD44 antibody.
A: Representative sorting images of the cells treated with lower or higher concentration, of which value is close to IC50 of the compounds 
(Fig. 2), with the ratio of CD44-positive cells. B: Quantification of CD44-positive cells treated with lower or higher concentration, of 
which value is close to IC50. *P < 0.05, **P < 0.01, compared between two groups. The statistics were examined by one-way ANOVA, 
followed by Tukey HSD test. Data are shown as mean ± SD of three experiments. 5-FU, 5-fluorouracil; DMSO, dimethylsulfoxide; IC50, 
inhibitory concentration 50.
enin signal is an evolutionary conserved developmental 
pathway, which is crucial for self-renewal and differen-
tiation of CSCs.12, 13 Since we have recently developed 
small molecule compounds, the derivatives of Wnt/be-
ta-catenin signal inhibitors that efficiently suppress Wnt/
beta-catenin transcriptional activity of human MSCs,16, 
17 we tested the effects of these inhibitors on HSC2 
OSCC cells. Here, we showed that HC-1, IC-2 and PN3-
13 reduced Wnt/beta-catenin signal in HSC2 cells. Of 
these compounds, HC-1 showed efficient reduction of 
CD44-positive population without affecting cell viabil-
ity. In addition, HC-1 sensitized HSC2 cells to 5-FU, 
which inhibits the synthesis of DNA/RNA in non-CSCs. 
These results suggest that HC-1 is an effective com-
pound to enhance the cytotoxicity of the cells by shifting 
CSCs to non-CSCs (Fig. 4E).
 It has been reported that one of the first successes 
of differentiation therapy is to use all-trans retinoic acid 
(ATRA), which was given to patients suffering from 
acute promyelocytic leukemia.25 ATRA treatment stim-
ulates the shift of abnormal leukemic promyelocytes 
into mature granulocytes, and markedly improves pa-
tient survival.26 The success of this therapy has induced 
the concept that changes of the cell state are effectively 
used to treat other forms of cancers. The other agents 
that have similar effects to change the leukemic cell 
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state include phorbol myristate acetate (PMA), hexam-
ethylamine bisacetamide (HMBA), DMSO and vitamin 
D3.27–30 Since HC-1 efficiently shifted CSCs to non-
CSCs in OSCC cells, HC-1 may also be beneficial for 
cancer therapy. HC-1 is a derivative of hexachlorophene. 
Hexachlorophene inhibits Wnt/beta-catenin signal by 
promoting E3 ubiquitin-protein ligase SIAH1-depen-
dent degradation of beta-catenin.21 Consistent with this, 
Western blot analysis showed that HC-1 also decreased 
protein levels of beta-catenin (Fig. 4D), suggesting that 
HC-1 inhibits Wnt/beta-catenin signal through beta-cat-
enin reduction. Therefore, beta-catenin degradation 
may be associated with the reduction of CSC popula-
tion. Further studies are required to reveal the crucial 
function of HC-1 in shifting CSCs to non-CSCs, which 
would also facilitate understanding of CSC property and 
Fig. 4. Combined treatment using 5-FU and HC-1 increases the rate of apoptotic cell death.
A: HSC2 cells were treated with increasing concentration of 5-FU alone or in combination with 50 µM HC-1 for 48 h. Cell viability was 
analyzed by WST assay. *P < 0.05, compared between with and without HC-1. The statistics were examined by unpaired Student’s t-test. 
Data are shown as mean ± SD of three experiments. At 10 µM 5-FU, P value was 0.066. B: Cells were treated with DMSO, 0.1 µM 5-FU, 
50 µM HC-1 or combination of 5-FU and HC-1 for 48 h. The representative cell images are shown [phase contrast (upper), annexin-V 
staining (middle) and PI staining (lower)]. Bar = 500 µm. C: Quantification of annexin-V (+) and PI (+) cells. Ten fields were randomly 
chosen, photographed from each group, and statistically analyzed. *P < 0.05, **P < 0.01, compared between two groups. The statistics 
were examined by one-way ANOVA, followed by Games-Howell test. Data are shown as mean ± SD of 10 fields. D: Western blot anal-
ysis of beta-catenin using HSC2 cells treated with DMSO, 50 µM or 100 µM HC-1 for 48 h. Actin was used as an internal control. E: 
Model of the chemotherapeutic effect of combined treatment with HC-1 and 5-FU to CD44-positive OSCC cells. Wnt/beta-catenin inhib-
itor HC-1 stimulates shift of CD44-positive cells (CSCs) to CD44-negative cells (non-CSCs), and sensitizes HSC2 cells to 5-FU through 
enhancement of apoptotic cell death. 5-FU, 5-fluorouracil; CSC, cancer stem cell; DMSO, dimethylsulfoxide; OSCC, Oral squamous cell 
carcinoma.
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development of cancer chemotherapy.
Acknowledgments: We thank Dr. T. Sakabe for helpful discussion 
on this manuscript. This work was supported by a Management 
Expenses Grant from the Ministry of Education, Culture, Sports, 
Science and Technology, Japan.
The authors declare no conflict of interest. 
REFERENCES
  1 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, 
Parkin DM. Estimates of worldwide burden of cancer in 2008: 
GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917. PMID: 
21351269.
  2 Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, 
Sivachenko A, et al. The mutational landscape of head and 
neck squamous cell carcinoma. Science. 2011;333:1157-60. 
PMID: 21798893.
  3 Hunter KD, Parkinson EK, Harrison PR. Profiling early head 
and neck cancer. Nat Rev Cancer. 2005;5:127-35. PMID: 
15685196.
  4 Gupta S, Kong W, Peng Y, Miao Q, Mackillop WJ. Temporal 
trends in the incidence and survival of cancers of the upper 
aerodigestive tract in Ontario and the United States. Int J Can-
cer. 2009;125:2159-65. PMID: 19569190.
  5 Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, 
Kaplan MJ, Dalerba P, et al. Identification of a subpopula-
tion of cells with cancer stem cell properties in head and 
neck squamous cell carcinoma. Proc Natl Acad Sci USA. 
2007;104:973-8. PMID: 17210912.
  6 Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular 
biology of head and neck cancer. Nat Rev Cancer. 2011;11:9-
22. PMID: 21160525.
  7 Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, 
cancer, and cancer stem cells. Nature. 2001;414:105-11. PMID: 
11689955.
  8 Shackleton M, Quintana E, Fearon ER, Morrison SJ. Hetero-
geneity in cancer: cancer stem cells versus clonal evolution. 
Cell. 2009;138:822-9. PMID: 19737509.
  9 Meacham CE, Morrison SJ. Tumour heterogeneity and cancer 
cell plasticity. Nature. 2013;501:328-37. PMID: 24048065.
10 Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl 
J Med. 2006;355:1253-61. PMID: 16990388.
11 Cabrera MC, Hollingsworth RE, Hurt EM. Cancer stem cell 
plasticity and tumor hierarchy. World J Stem Cells. 2015;7:27-
36. PMID:16990388.
12 Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: 
can we safely eradicate cancer stem cells?. Clin Cancer Res. 
2010;16:3153-62. PMID: 20530697.
13 Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer 
stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. 
Nat Rev Clin Oncol. 2011;8:97-106. PMID: 21151206.
14 Yoshida Y, Shimomura T, Sakabe T, Ishii K, Gonda K, 
Matsuoka S, et al. A role of Wnt/beta-catenin signals in he-
patic fate specification of human umbilical cord blood-derived 
mesenchymal stem cells. Am J Physiol Gastrointest Liver 
Physiol. 2007;293:G1089-98. PMID: 17884977.
15 Shimomura T, Yoshida Y, Sakabe T, Ishii K, Gonda K, 
Murai R, et al. Hepatic differentiation of human bone mar-
row-derived UE7T-13 cells: Effects of cytokines and CCN 
family gene expression. Hepatol Res. 2007;37:1068-79. PMID: 
17627621.
16 Itaba N, Matsumi Y, Okinaka K, Ashla AA, Kono Y, Osaki M, 
et al. Human mesenchymal stem cell-engineered hepatic 
cell sheets accelerate liver regeneration in mice. Sci Rep. 
2015;5:16169. PMID: 26553591.
17 Itaba N, Sakabe T, Kanki K, Azumi J, Shimizu H, Kono Y, 
et al. Identification of the small molecule compound which 
induces hepatic differentiation of human mesenchymal stem 
cells. Regenerative Therapy. 2015;2:32-41. DOI: 10.1016/
j.reth.2015.10.001.
18 Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mech-
anisms of action and clinical strategies. Nat Rev Cancer. 
2003;5:330-8. PMID: 12724731.
19 Lepourcelet M, Chen YN, France DS, Wang H, Crews P, 
Petersen F, et al. Small-molecule antagonists of the oncogenic 
Tcf/beta-catenin protein complex. Cancer cell. 2004;5:91-102. 
PMID: 14749129.
20 Voronkov A, Krauss S. Wnt/beta-catenin signaling and small 
molecule inhibitors. Curr Pharm Des. 2013;19:634-64. PMID: 
23016862.
21 Park S, Gwak J, Cho M, Song T, Won J, Kim DE, et al. Hexa-
chlorophene inhibits Wnt/beta-catenin pathway by promoting 
Siah-mediated beta-catenin degradation. Mol Pharmacol. 
2006;70:960-6. PMID: 16735606.
22 Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, 
et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer 
stem cells: clinical update. Nat Rev Clin Oncol. 2015;12:445-
64. PMID: 25850553.
23 Espinoza I, Miele L. Notch inhibitors for cancer treatment. 
Pharmacol Ther. 2013;139:95-110. PMID: 23458608.
24 Beachy PA, Hymowitz SG, Lazarus RA, Leahy DJ, Siebold C. 
Interactions between Hedgehog proteins and their binding 
partners come into view. Genes Dev. 2010;24:2001-12. PMID: 
20844013.
25 Warrell RP Jr., de Thé H, Wang ZY, Degos L. Acute promy-
elocytic leukemia. N Engl J Med. 1993;329:177-89. PMID: 
8515790.
26 Mi JQ, Li JM, Shen ZX, Chen SJ, Chen Z. How to manage 
acute promyelocytic leukemia. Leukemia. 2012;26:1743-51. 
PMID: 22422168.
27 Carey JO, Posekany KJ, deVente JE, Pettit GR, Ways DK. 
Phorbol ester-stimulated phosphorylation of PU.1: association 
with leukemic cell growth inhibition. Blood. 1996;87:4316-24. 
PMID: 8639791.
28 Wu H, Scher BM, Chu CL, Leonard M, Olmedo R, Scher GS, 
et al. Reduction in lactate accumulation correlates with dif-
ferentiation-induced terminal cell division of leukemia cells. 
Differentiation. 1991;48:51-8. PMID: 1683843.
29 Arcangeli A, Carlà M, Del Bene MR, Becchetti A, Wanke E, 
Olivotto M. Polar/apolar compounds induce leukemia cell 
differentiation by modulating cell-surface potential. Proc Natl 
Acad Sci USA. 1993;90:5858-62. PMID: 8516337.
30 Olsson I, Gullberg U, Ivhed I, Nilsson K. Induction of dif-
ferentiation of the human histiocytic lymphoma cell line 
U-937 by 1 alpha, 25-dihydroxycholecalciferol. Cancer Res. 
1983;43:5862-7. PMID: 6315218.
